[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"survival\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:survival":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,52,88,112,135,157,185,210,237,263,291,322,352,377,402],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100638808","phase-4-long-term-follow-up-of-dexmedetomidine-esketamine-and-tdcs-for-neurocognitive-complications-after-surgery-100638808",false,"NCT07576543","Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery","Long-term Follow-up of Perioperative Dexmedetomidine-esketamine Combination and Transcranial Direct Current Stimulation for Prevention of Neurocognitive Complications in Older Patients After Non-cardiac Surgery","Inclusion Criteria:\n\n* Aged 65 to 90 years;\n* Preoperative Mini-Mental State Examination (MMSE) score \\\u003C 27 points, indicating possible cognitive impairment ranging from mild to moderate;\n* Scheduled to undergo elective non-cardiac, non-neurosurgical surgery under general anesthesia, with an expected surgical duration \\> 1 hour;\n* Required patient-controlled intravenous analgesia (PCIA) after surgery.\n\nExclusion Criteria:\n\n* Preoperative inability to communicate due to coma, severe dementia, endstage disease, or language impairment;\n* History of schizophrenia, epilepsy, Parkinson's disease, brain trauma\u002Fsurgery, or myasthenia gravis;\n* Presence of metal implants in the intracranial or cervical region (such as cochlear implants, aneurysm clips, deep brain stimulation electrodes), or skin damage or severe skin disease on the head;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C 30%), comorbid with sick sinus syndrome, severe bradycardia (heart rate \\\u003C 50 bpm), or second-degree or higher atrioventricular block, or implantation of a cardiac pacemaker;\n* Uncontrolled hyperthyroidism or pheochromocytoma;\n* Severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (requiring dialysis), or ASA classification ≥ IV;\n* Allergy to dexmedetomidine or esketamine;\n* Participation in other clinical studies within the past 3 months;\n* Other conditions that are deemed unsuitable for study participation.",true,"ALL","65 Years","90 Years",{"count":21,"type":22},1160,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Neurocognitive complications, mainly delirium and neurocognitive disorders, are common cerebral complications in older patients after surgery and associated with worse long-term outcomes. An ongoing 2×2 factorial trial conducted by the investigators plan to test the effects of perioperative dexmedetomidine-esketamine combination and transcranial direct current stimulation (tDCS) on postoperative neurocognitive complications in older patients. This long-term follow-up of the ongoing trial aims to investigate the effects of perioperative dexmedetomidine-esketamine combination and tDCS on long-term outcomes in older patients after noncardiac surgery.",[28,29,30,31,32,33,34],"Older Patients","Surgery","Dexmedetomidine","Esketamine","Transcranial Direct Current Stimulation","Cognitive Function","Survival",[36,29,30,31,37,38,34],"Older patients","Transcranial direct current stimulation","Cognitive function","NOT_YET_RECRUITING","2026-05-07",{"date":42,"type":43},"2026-05-12","ACTUAL",{"date":45,"type":22},"2026-06",{"date":47,"type":22},"2031-06",{"name":49,"class":50},"Peking University First Hospital","OTHER",6,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370","NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","2 Years","35 Years",{"count":62,"type":22},96,[64,65],"PHASE2","PHASE3","Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[68,69,70,71,72,34,73,74,75],"Classical Hodgkin Lymphoma","Child","Adolescent","Young Adult","Metabolic Response","Treatment","Brentuximab Vedotin","PET Scan","RECRUITING","2026-03-17",{"date":79,"type":43},"2026-03-19",{"date":81,"type":43},"2024-09-25",{"date":83,"type":22},"2039-11-15",{"name":85,"class":86},"Children's Cancer Group, China","NETWORK",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":16,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":87},"100605334","changes-in-body-composition-of-patients-with-obesity-related-tumors-and-their-impact-on-clinical-outcomes-a-multicenter-prospective-cohort-study-100605334","NCT07161167","Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender.\n2. Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted).\n3. No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy.\n\nExclusion Criteria:\n\n1. Patients with concurrent non-obesity-related malignancies.\n2. History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin).\n3. Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.","18 Years",{"count":96,"type":22},6743,"OBSERVATIONAL","Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA\u002FCT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat\u002Fmuscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.",[100,101,34,102],"Obesity Rekated Cancer","Body Composition Changes","Mechanism","2025-09-03",{"date":105,"type":43},"2025-09-08",{"date":107,"type":22},"2025-09-15",{"date":109,"type":22},"2030-09-30",{"name":111,"class":50},"Peking Union Medical College Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":87},"100436394","anesthesia-induced-brain-cancer-survival-abc-survival-a-feasibility-study-100436394","NCT04962672","Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study","Inclusion Criteria:\n\n1. Patient presenting between Jul 1, 2022 and Dec 28, 2023 for elective procedure\n2. Males or females of \\>18 years\n3. Patient will be undergoing primary craniotomy (with general anesthesia) for suspected high-grade primary glial brain tumor (WHO grade III and IV)\n\nExclusion Criteria:\n\n1. Patients of pediatric age group and pregnant patients\n2. Patients previously diagnosed with severe adrenal dysfunction (over activity or insufficiency)\n3. Suspected low grade (grade I, II), glioma, tumors involving brainstem and optic tract, and as well as non-glial tumors (i.e. suspected brain metastasis)\n4. Awake craniotomies\n5. Any conditions that preclude postoperative MRI\n6. Motor evoked potential monitoring or any other intraoperative condition that renders choice of anesthetics affected.\n7. Recurrent GBM",{"count":119,"type":22},40,[121],"NA","Cancer is a leading cause of death worldwide. It is estimated that approximately 55,000 Canadians are surviving with brain tumors. It is projected that around 3000 persons will be diagnosed with brain and spinal cord tumors, and approximately 75 percent patients will not survive. Out of all brain cancers, high-grade gliomas \\[Glioblastoma Multiforme (GBM)\\] impose highest morbidity and mortality. Therefore, it is important to explore ways in which Investigators can improve and prolong the lives of patients suffering from brain cancers, particularly high-grade glioma, which is the most common and aggressive primary brain tumor.\n\nSo far the Investigators know that the surgery, chemotherapy and radiotherapy are the three corner stones management options for these patients, and majority of the research have been conducted on these three major domains. Therefore, it is imperative to explore the other variables those may impact survival characteristics. One of the integral variables of the brain cancer surgery is anesthesia. Interestingly, the role of anesthetics was explored in some other non-brain solid organ tumor surgeries. It is observed that out of the two main types of anesthesia \\[one is through intravenous (propofol) and other one is gaseous (sevoflurane)\\], intravenous based anesthesia maintenance regime may delay the cancer progression and prolong the recurrence free period. In addition, two very large retrospective studies with approximately 11,000 and 18,000 patients respectively, showed that as compared to gaseous (volatile anesthetics) based, intravenous (propofol) based anesthesia conferred some protection against cancer progression and was also associated with lesser overall mortality. The exact nature of these protective mechanisms is not known but in animal and other laboratory-based experiments, propofol seems to inhibit cancer formation steps, delays inflammation and provide protection from cancer cell growth. This is a feasibility study for knowing various aspects of workflow; recruitment characteristics of participants and various obstacles in implying anesthesia based protocols so that the Investigators can conduct a well-designed multicenter international randomized study.",[124,125,34],"Anesthesia","Brain Cancer","2025-01-29",{"date":128,"type":43},"2025-01-31",{"date":130,"type":43},"2022-01-01",{"date":132,"type":22},"2025-09-30",{"name":134,"class":50},"University Health Network, Toronto",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":87},"100564319","radical-surgery-for-advanced-gastric--or-gej-cancer-with-oligometastatic-dissmination-to-the-liver-100564319","NCT06627634","Radical Surgery for Advanced Gastric- or GEJ-cancer With Oligometastatic Dissmination to the Liver","Gastric Cancer and Oligometastatic Liverinvolvement. Metastatectomy and Impact on Survival","LEVECA","Inclusion Criteria:\n\n* Age \\> 18.\n* Presence of primary T1-T4N0-N3M1 adenocarcinoma of the stomach or GEJ and max. 30% liver involvement.\n* Primary tumour resectable, based on imaging workup.\n* Surgical operable patients with ASA-score36 ≤ III and WHO performance status37 0-1.\n* Patients eligible for treatment with systemic chemotherapy by FLOT regimen.\n* Informed consent is obtained.\n\nExclusion Criteria:\n\n* Patient with non-resectable cancer.\n* Direct growth involving adjacent organs, i.e., pancreas, colon, blood vessels or bones.\n* Other malignant disease diagnosed or treated up to 2 years prior to inclusion, except non-aggressive cancers such as non-melanoma sin cancer.\n* Altered anatomy of the upper gastrointestinal tract due to previous surgery of the oesophagus, stomach, and duodenum.\n* BMI ≤ 18\n* The patient is unable to understand and\u002For read the consent form.\n* Other serious illness or acute infections.\n* Pregnant or breastfeeding.",{"count":144,"type":22},20,[121],"Offering treatment with potential to cure for participants with no such offer in today's standard treatment options, by offering metastatectomia and standard treatment with intention to cure i.e., neoadjuvant chemotherapy and gastrectomy for participants with gastric- og gastroeusofageal junction cancer. Including 20 participants from all 4 centres in Denmark able to perform the surgical procedures in question.\n\nEndpoints: 2-year overall survival.",[34],"2024-10-03",{"date":150,"type":43},"2024-10-04",{"date":152,"type":43},"2020-12-01",{"date":154,"type":22},"2024-12-01",{"name":156,"class":50},"Aarhus University Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":87},"100527393","comparison-of-long-term-survival-and-quality-of-life-after-minimally-invasive-esophagectomy-versus-open-esophagectomy-100527393","NCT06147180","Comparison of Long-term Survival and Quality of Life After Minimally Invasive Esophagectomy Versus Open Esophagectomy","Comparison of Long-term Survival and Quality of Life After Minimally Invasive Esophagectomy Versus Open Esophagectomy for Esophageal Cancer: a Retrospective Cohort Study","Inclusion Criteria:\n\n1. Patients who had undergone esophageal cancer resection at the Department of Thoracic Surgery, Qilu Hospital, Shandong University, between 2013 and 2021, with pathology results confirming esophageal squamous carcinoma, adenocarcinoma, or other malignant tumors.\n2. The surgery was successfully completed, the patient was safely discharged from the hospital, the postoperative follow-up was successful, and if the follow-up patient died, his or her death was due to natural causes.\n\nExclusion Criteria:\n\nPerioperative patient deaths, pathologic findings other than those listed above, loss of visits, and postoperative unnatural deaths.",{"count":165,"type":22},1474,"To analyze and compare the long-term recurrence-free survival rate, overall survival rate and quality of survival after minimally invasive esophagectomy and open esophagectomy, and to conduct subgroup analysis according to the type of esophageal cancer and pathological stage, etc., and to explore more deeply the differences between minimally invasive esophagectomy and open esophagectomy in terms of the benefits for different types of patients, so as to provide reference for the selection of the clinical surgical methods. We will also use the available data to analyze the influence of other factors on patients\\' long-term survival after surgery.",[168,169,170,34],"Esophagus Cancer","Esophagectomy","Quality of Life",[172,173,174,175,176],"esophagus Cancer","invasive esophagectomy","open esophagectomy","long-term survival","quality of life","2023-11-19",{"date":179,"type":43},"2023-11-27",{"date":179,"type":22},{"date":182,"type":22},"2026-08-31",{"name":184,"class":50},"Qilu Hospital of Shandong University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100525256","incremental-pd-with-single-icodextrin-exchange-100525256","NCT06119373","Incremental PD With Single Icodextrin Exchange","Initiation of Incremental Dialysis With Single Daily Icodextrin Exchange: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. male or female patients aged 18 to 75 years;\n2. patients with chronic kidney disease stage 5 who are to start PD;\n3. eGFR ≥ 5 ml\u002Fmin;\n4. urine output ≥ 800 ml\u002Fd.\n\nExclusion Criteria:\n\n1. documented anaphylaxis with icodextrin or glucose-based dialysate;\n2. concomitant severe chronic diseases such as malignancy, hepatitis, severe cardiac diseases, etc.;\n3. ongoing severe infection;\n4. planned or ongoing pregnancy or lactation;\n5. currently enrolled in other clinical studies;\n6. patients who have a life expectancy of \\\u003C12 months;\n7. refusal to give a written consent.","75 Years",{"count":194,"type":22},72,[121],"Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD).\n\nSubjects: Seventy-two incident PD patients.\n\nMethods: A single-center randomized controlled trial.\n\nPrimary outcome: Change in residual kidney function in 48 weeks after recruitment.",[198,199,34,200],"Peritoneal Dialysis Complication","Residual Kidney Function","Health-related Quality of Life","2023-11-05",{"date":203,"type":43},"2023-11-08",{"date":205,"type":22},"2023-12-01",{"date":207,"type":22},"2026-11-30",{"name":209,"class":50},"RenJi Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":87},"100519915","d2-versus-d3-dissection-in-laparoscopic-right-hemicolectomy-100519915","NCT06049758","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy In Right Cancer Colon Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with right-side colon cancer (caecum, ascending, or hepatic flexure)\n* Diagnosed by CT entero-colonography\n* Diagnosed by colonoscopy\n* Diagnosed by biopsy.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction, perforation with generalized peritonitis),\n* Metastatic tumor diagnosed\n* ASA score of IV or higher\n* Need for more than one surgical procedure\n* Conversion to open surgery",{"count":218,"type":22},80,[121],"Evaluating the differences between D2 and D3 lymphadenectomy in laparoscopic right hemicolectomy in patients with right cancer colon post-operative outcome, intra-operative blood transfusion, post-operative ICU admission, anastomotic leakage, lymph node harvesting in the final specimen, and six months follow up and overall survival time after 5-years",[222,223,224,225,34,226],"Blood Loss","Intensive Care","Anastomotic Leakage","Lymph Node Disease","Blood Transfusion","2023-09-19",{"date":229,"type":43},"2023-09-22",{"date":231,"type":22},"2024-01-02",{"date":233,"type":22},"2030-01-02",{"name":235,"class":236},"General Committee of Teaching Hospitals and Institutes, Egypt","OTHER_GOV",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":192,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":87},"100384064","phase-3-neo-adjuvant-immunochemotheray-versus-neo-adjuvant-chemotherapy-for-resectable-esophageal-carcinoma-100384064","NCT04280822","Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma","A Phase III, Randomized Controlled Study of Neo-adjuvant Toripalimab (JS001) in Combination With Chemotherapy Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Histologic diagnosis of local advance squamous cell thoracic esophageal carcinoma of Stage (T1N1-3 or T2-3N0-3 M0), (8th Union for International Cancer Control, UICC-TNM).\n2. No metastatic lymph node in cervical by color doppler sonography.\n3. Patients must not have received any prior anticancer therapy of esophageal carcinoma.\n4. Age ranges from 18 to 75 years.\n5. Without operative contraindication.\n6. Absolute white blood cells count ≥4.0×109\u002FL, neutrophil ≥1.5×109\u002FL, platelets ≥100.0×109\u002FL, hemoglobin ≥90g\u002FL, and normal functions of liver and kidney, total bilirubin（TBIL）≤1.5N, aspartate aminotransferase (AST)≤2.5N, alanine aminotransferase(ALT)≤2.5N, prothrombin time(PT)≤1.5N, and activated partial thromboplastin time(APTT) is in normal range, endogenous creatinine clearance rate(CRE)≤1.5N.\n7. Patients must not have diagnosed with other cancer and must not received any prior anticancer therapy except prostatic cancer with more than 5 years disease-free survival(DFS).\n8. expected R0 resection.\n9. ECOG 0～1.\n10. Patients should agree to use contraceptive measures during the study period and within 6 months of the end of the study. Women must be non-lactation.\n11. Signed informed consent document on file. 10. .\n\nExclusion Criteria:\n\n* 1\\. Multiple primary cancer. 2.Patients with infections disease that require treatment 3.Patients who need continuous hormone treatment 4.unstable angina within 3 months, myocardial infarction within 6 months 5.psychopath 6.Patients with concomitant hemorrhagic disease. 7.Any unexpected reason for patients can't get operation 8.Inability to use gastric conduit after esophagectomy because of a prior surgery.\n\n  9.Pregnant or breast feeding 10.Patients are diagnosed or suspected to be allergic to cisplatin or Paclitaxel.\n\n  11.Bronchial asthma who requires intermittent use of bronchodilators or medical interventions 12.Due to co-existing diseases, the immunosuppressant was used. And the dosage of immunosuppressant was more than 10mg\u002F day orally and more than 2 weeks before enrollment 13.Abnormal coagulation function (PT\\>16s, APTT\\>53s, TT\\>21s, Fib\\\u003C1.5g\u002FL), tendency of bleeding or receiving thrombolysis or anticoagulant therapy 14.Previous or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, lung function severely impaired 15.Autoimmune diseases, immune deficiency, organ transplantation； 16.Hepatitis b\u002Fc patients。",{"count":245,"type":22},400,[65],"The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.",[249,29,250,34],"Esophageal Cancer","Neoadjuvant Treatment",[252,253],"Neoadjuvant chemotherapy","Neoadjuvant immunochemotherapy","2022-10-02",{"date":256,"type":43},"2022-10-04",{"date":258,"type":43},"2020-04-21",{"date":260,"type":22},"2028-03-02",{"name":262,"class":236},"Henan Cancer Hospital",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":271,"minAge":94,"maxAge":192,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":279,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100461184","classified-treatment-strategy-for-de-novo-metastatic-breast-cancer-after-systemic-adjuvant-therapy-100461184","NCT05285332","Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy","Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapywhich Patients Will Benefit From Surgery","CS","Study Population Operable stage IV breast cancer patients, whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imaginology examination\n\nInclusion Criteria:\n\n* Operable stage IV breast cancer patients,whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imageology examination.\n* ECOG-PS 0-2.\n* Bone marrow, liver and kidney should be fully functional.\n* Patients didn't received the locoregional surgery of the primary tumor in de novo.\n* For the patient who accepted systematic treatment before operation, the systematic treatment must be administered within a year since diagnosed.\n\nExclusion Criteria:\n\n* Accompanied with other primary malignant tumors.\n* More than two visceral organ involvement.\n* Patients who can't plan for follow-up effectively and regularly.\n* Multiple liver metastases with deranged liver function tests (SGOT\u002FSGPT more than four times the upper normal limit).","FEMALE",{"count":273,"type":22},362,[121],"For patients with de novo stage IV breast cancer, the current debate is whether local surgery can improve the survival of patients. There is no clinical study on the classification after systemic treatment of de novo stage IV breast cancer patients. In fact, the clinical stage of tumor can change with the change of treatment. For example, the stage Ⅲ of locally advanced breast cancer can down-staging to the stage Ⅱ after systemic treatment. Similarly, patients with stage Ⅳ can down-staging to stage Ⅱ or stage Ⅲ after systemic treatment. At this time, the patient can receive surgical treatment. Therefore, this study is to first treat de novo stage IV breast cancer patients with systemic treatment, according to the response after systemic treatment to give different treatment measures（surgery or continued systemic treatment）. The investigators hope that this study will provide new ideas for the treatment of de novo stage IV breast cancer and other de novo stage IV cancers.",[277,73,278,34],"Breast Neoplasms","Metastatic Breast Cancer",[277,280,281],"de-novo metastatic breast cancer","surgical treatment","2022-07-17",{"date":284,"type":43},"2022-07-19",{"date":286,"type":22},"2022-08-01",{"date":288,"type":22},"2031-05-01",{"name":290,"class":50},"Changhai Hospital",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":192,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":307,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100427398","phase-2-comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy-100427398","NCT04845490","Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy","Comparative Study on the Efficacy of Mitomycin and Lobaplatin in the Treatment of Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy","WUHIPEC02","Inclusion Criteria:\n\n1. No chemoradiotherapy or other anti-tumor therapy before clinical trial performed;\n2. Aged 18-75 years;\n3. Male or non-pregnant or lactating women;\n4. Pathological diagnosis of colorectal adenocarcinoma;\n5. Clinical diagnosis of T3 stage or above without distant metastasis and can be given radical surgery (AJCC Version 8, 2018);\n6. Normal function of major organs;\n7. Routine blood examinations meeting the following criteria:\n\n   A. HB ≥ 90 g\u002FL; B. ANC ≥ 1.5 x 10 9 \u002FL; C. PLT ≥ 125 × 10 9 \u002FL;\n8. Chemistry indexs meeting the following criteria:\n\n   A. TBIL \\\u003C 1.5ULN; B. ALT and AST \\\u003C 2.5ULN; ALB \\> 30 g\u002FL C. serum Cr ≤ 1.25 ULN or endogenous creatinine clearance \\> 50 ml\u002Fmin (Cockcroft-Gault formula);\n9. ECOG score 0-1;\n\nExclusion Criteria:\n\n1. A history of other malignant tumors within 5 years;\n2. Distant metastasis found during surgery;\n3. Allergic to paclitaxel, lobaplatin and other related chemotherapeutic drugs;\n4. Suffering from epilepsy or other mental illness, unable to control behavior;\n5. Inability to tolerate surgery due to severe cardiac, pulmonary and vascular disease;\n6. Pregnant or lactating women.\n7. Receiving anti-cancer drug therapy from other clinical trials.",{"count":300,"type":22},201,[64],"This study is a prospective, randomized, comparative clinical trial conducted by Wuhan Union Hospital and aim to compare the therapeutic effects of Mitomycin and Lobaplatin in the treatment of advanced colorectal cancer patients with radical surgery combined with hyperthermic intraperitoneal chemotherapy",[304,305,29,306,34],"Colorectal Cancer","Chemotherapy Effect","Metastasis",[308,309,310,311,312],"advanced colorectal cancer","hyperthermic intraperitoneal chemotherapy","mitomycin","lobaplatin","prognosis","2022-02-18",{"date":315,"type":43},"2022-02-21",{"date":317,"type":22},"2022-09-01",{"date":319,"type":22},"2026-09-01",{"name":321,"class":50},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":328,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100402410","phase-iii-study-of-concurrent-radiotherapy-in-elderly-patients-with-esophageal-squamous-cell-carcinoma-eso-shanghai-15-100402410","NCT04519905","Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)","Inclusion Criteria:\n\n* Indicates no limit on eligibility based on the sex of participants\n* The 76 years old for the minimum age a potential participant must meet to be eligible for the clinical study.\n* Esophageal squamous cell carcinoma confirmed by pathology\n* No radiotherapy, chemotherapy or other treatments prior to enrollment\n* Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, TxNxM1b (M1b only for supraclavicular lymph node metastasis) (AJCC 6th)\n* Use of an effective contraceptive for adults to prevent pregnancy\n* No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function\n* No immunodeficiency\n* ECOG 0-1.\n* Life expectancy of more than 3 months.\n\nExclusion Criteria:\n\n* Total radiotherapy dose cannot reach 61.2Gy\u002F34Fx\n* Esophageal perforation, or hematemesis\n* History of radiotherapy or chemotherapy for esophageal cancer\n* History of surgery within 28 days before Day 1\n* History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years)\n* Participation in other interventional clinical trials within 30 days\n* Pregnant or breast-feeding women or fertile patients\n* Drug addiction,\n* alcoholism or AIDS\n* Uncontrolled seizures or psychiatric disorders","76 Years",{"count":330,"type":22},320,[121],"So far, there is no specific clinical guideline for elderly patients (\\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy\u002F34Fx） or the chemoradiotherapy group (50.4Gy\u002F28Fx；Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.",[334,335,34],"Esophageal Squamous Cell Carcinoma","Chemoradiotherapy",[337,338,339,340,341],"esophageal squamous cell carcinoma","elderly patients","chemoradiotherapy","definitive radiotherapy","survival","2021-10-31",{"date":344,"type":43},"2021-11-02",{"date":346,"type":43},"2020-01-06",{"date":348,"type":22},"2027-12",{"name":350,"class":50},"Fudan University",3,{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":87},"100439010","long-term-survivorship-of-discharged-patients-with-malignant-tumor-based-on-single-institutional-cancer-registry-100439010","NCT04996732","Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry","Studies on Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Fudan University Shanghai Cancer Center Registry（FUCaRe）","Inclusion Criteria:\n\n* All patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative evaluation in Fudan University Shanghai Cancer Center during the study period.\n\nExclusion Criteria:\n\n* Patients who have not been treated during hospitalization;\n* Patients with non-malignant tumors.",{"count":360,"type":22},500000,"Real-world studies on long-term prognosis in patients who underwent anti-tumor treatments during hospitalization from a hospital-based cancer registry in china.",[363,34,29,364,365],"Neoplasms","Radiotherapy","Drug Therapy",[367,368],"Cancer","Survivorship","2021-08-02",{"date":371,"type":43},"2021-08-09",{"date":373,"type":43},"2008-01-01",{"date":375,"type":22},"2041-12-31",{"name":350,"class":50},{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":87},"100430856","phase-2-an-open-label-multicentre-phase-iiiii-rct-of-pfll-versus-gp-combined-with-js001-as-the-first-line-therapy-for-mnpc-100430856","NCT04890522","An Open-label, Multicentre, Phase II\u002FIII RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC","A Randomized, Open-label, Multicentre, Phase II\u002FIII Study of Low-dose Long-term Continuous Intravenous Infused 5-fluorouracil Versus Gemcitabine Combined With Cisplatin and JS001 as First-line Therapy for Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Nasopharyngeal carcinoma diagnosed by pathology or cytology.\n* Primarily metastatic (stage IVB as defined by the International Union against Cancer and American Joint Committee on Cancer staging system for NPC, eighth edition) is not amenable for local-regional treatment or curative treatment.\n* Has not received prior systemic treatment for metastatic nasopharyngeal carcinoma, except for neoadjuvant chemotherapy, concurrent chemoradiotherapy, or adjuvant chemotherapy 6 months prior to the first treatment.\n* The Karnofsky performance status score is at least 70 points (if the decreased score is caused by the tumor, the minimum score can be 50 points after the judgment of researchers.)\n* Has at least one measurable target lesion based on RECIST v1.1, which is never received local treatment like radiotherapy.\n* Life expectancy ≥ 3 months.\n* The lab examination results of the screening must fulfill all of the following (use of any blood components, hematopoietic stimulating factors, etc. are not allowed within 14 days before screening):\n\n  1. absolute neutrophil count ≥1.5×10\\^9\u002F L;\n  2. platelet count ≥ 100×10\\^9\u002F L;\n  3. hemoglobin ≥ 8.0 g\u002FdL;\n  4. serum albumin ≥ 2.8g\u002FdL;\n  5. aspartate transferase(AST) and alanine transferase(ALT) ≤ 1.5 ×ULN; total bilirubin ≤ 1.5×ULN (if has liver metastasis, AST and ALT ≤ 5×ULN);\n  6. creatinine clearance \\>50 mL\u002Fmin.\n* Men with reproductive capacity or women of childbearing potential must use highly effective contraceptive methods during the trial (e.g., oral contraceptives, intrauterine device, sexual abstinence or barrier method combined with spermicide), and continue contraception for 3 months after the last injection of JS001 and 6 months after the end of chemotherapy.\n* Has signed the Informed Consent Form.\n\nExclusion Criteria:\n\n* Allergic to monoclonal antibodies, any JS001 components, gemcitabine, cisplatin, or 5-fluorouracil.\n* Has prior therapy including anti-PD-1, anti-PD-L1, or CTLA4.\n* Major surgery within 28 days prior to the randomization (not including diagnostic surgery) or plan to be conducted during the study.\n* Active autoimmune disease requiring systemic treatment or has a history of autoimmune disease.\n* Requiring the use of cortisol (\\>10mg\u002Fday Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment.\n* Allergic to macromolecular protein preparation ingredients.\n* Has central nervous system (CNS) metastasis with clinical symptoms.\n* Had other invasive malignant diseases, except excised basal-cell skin carcinoma, cervical carcinoma in situ, or other cancers curatively treated more than 5 years before study entry.\n* Has cardiac clinical symptoms or disease out of control.\n* Has an active infection or unexplained fever with more than 38.5 ℃ during screening and prior to first administration.\n* Has acquired or congenital immune-deficient disease, or active hepatitis.\n* History of drug abuse or alcohol abuse.\n* The investigator judges other factors that may lead to the forced termination of this study, including but not limited to: other serious conditions (including mental disorder) that require concomitant treatment, severe laboratory test abnormalities, family or social factors that may affect the safety of patients or the collection of trial data and samples.\n* Pregnancy or breast feeding.","60 Years",{"count":386,"type":22},622,[64,65],"The treatment of distant metastasis is a key challenge for nasopharyngeal carcinoma because of poor outcomes, among which, chemotherapy is the cornerstone. However, many studies reported the use of different chemotherapy regimens to prolong the survival of metastatic nasopharyngeal carcinoma, while few of them focused on how to reduce the side effects of chemotherapy or improve the life quality of patients. Blocking the immune checkpoint is one of the effective strategies of tumor immunotherapy. Thus, we sought to find a proper chemotherapy regimen combined with PD-1 antibody JS001.",[390,306,391,392,34],"Nasopharyngeal Carcinoma","Chemotherapy","Immunotherapy","2021-05-16",{"date":395,"type":43},"2021-05-18",{"date":397,"type":22},"2021-07-01",{"date":399,"type":22},"2028-12-31",{"name":401,"class":50},"Sun Yat-sen University",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":410,"minAge":411,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":432},"100356363","salvage-hypofractionated-accelerated-versus-standard-radiotherapy-for-biochemical-failure-after-prostatectomy-100356363","NCT03920033","Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy","Comparison of Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy (SHARE Trial): a Prospective, Randomized Controlled, Open-label, Multi Center, Superiority Study","SHARE","Inclusion Criteria:\n\n* Pathologically confirmed intermediate- or high-risk prostate cancer\n* Biochemical recurrence after radical prostatectomy (Definition: Serial elevation of PSA over 0.2 ng\u002FmL and \\\u003C=1.0 ng\u002FmL)\n* ECOG performance status 0-1\n* Appropriate values of blood tests within 6 months after enrollment Absolute neutrophil count (ANC) ≥ 1500 cells\u002Fmm3 Platelets ≥ 50,000 cells\u002Fmm3 Hemoglobin ≥ 8.0 g\u002Fdl\n* Appropriate values of kidney function within 6 months after enrollment Creatinine \\\u003C 2.0 ng\u002FdL\n* Appropriate values of liver function within 6 months after enrollment total bilirubin \\\u003C 1.5 X maximum normal value alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5 X maximum normal value\n\nExclusion Criteria:\n\n* Clinically gross recurrent tumor\n* Presence of distant metastasis\n* Presence of pelvic LN metastasis\n* History of pelvic irradiation\n* History of cryotherapy or brachytherapy for prostate cancer\n* Double primary cancer other than skin\u002Fthyroid cancer\n* Combined serious morbidity","MALE","20 Years",{"count":413,"type":22},288,[121],"Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a control group of standard treatment group (66 Gy, 33 fractions). The criteria for stratification at randomization include 1) risk groups, 2) androgen deprivation therapy, and 3) PSA before salvage radiation therapy, which affect biochemical recurrence.\n\nIt is expected that hypofractionated, accelerated high dose radiation therapy will have a superiority in terms of biochemical control to conventional radiation therapy, and the present study would like to confirm this. In addition, we aimed to evaluate and compare the toxicity and quality of life index of two radiation therapy regimens.",[417,418,419,420,421,34,422,170],"Prostate Cancer","Biochemical Recurrence","Radiation","Hypofractionation","Dose Escalation","Radiation Toxicity","2021-01-15",{"date":425,"type":43},"2021-01-20",{"date":427,"type":43},"2019-05-01",{"date":429,"type":22},"2027-01-01",{"name":431,"class":50},"Asan Medical Center",2]